Celyad Oncology SA (EBR: CYAD)

Market Cap	9.94M
Revenue	102.00K
Net Income	-8.45M
Shares Out	41.43M
EPS	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,119
Open	0.240
Previous Close	0.240
Day's Range	0.240 - 0.250
52-Week Range	0.212 - 0.922
Beta	1.51
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 20, 2024

About Celyad Oncology

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement wi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 19
• Stock Exchange: Euronext Brussels
• Ticker Symbol: CYAD